combacte-net News Item

COMBACTE-NET Collaborates with Janssen in New Trial

The EXPECT-1 and EXPECT-2 studies are the newest members of the COMBACTE-NET consortium. EXPECT stands for EXtraintestinal Pathogenic Escherichia Coli Trial. The project is led by Marc Bonten from the University Medical Centre Utrecht (Netherlands) as the sponsor and Peter Hermans from Janssen Vaccines as EFPIA lead.

Extraintestinal pathogenic Escherichia coli (ExPEC) are a leading and rising cause of bacterial invasive disease worldwide. The emergence of multidrug resistance among ExPEC strains such as E. coli sequence type 131:O25B, represents a major challenge for the treatment of ExPEC infections. Prevention is becoming more and more important however to date, there is no vaccine available to prevent invasive ExPEC disease (IED).

The EXPECT-1 study is a prospective observational pilot study to assess success factors and barriers for a future Phase 3 randomized controlled trial, where the efficacy of a new vaccine to prevent invasive ExPEC disease will be tested in community-dwelling adults. General practitioners (GPs) in a maximum of 8 countries will be asked to recruit a total of 6,000 study participants (750 per country). These are adults aged 60 years or older in stable health, primarily with a history of urinary tract infections. The objective is to capture any hospitalization, with a focus on hospitalization due to IED, and to identify the clinical and operational challenges that might occur during the Phase 3 vaccine efficacy study.

The EXPECT-2 study is a prospective epidemiological study in the same hospitals participating in the EXPECT-1 study. In addition to participants enrolled by GPs in the EXPECT-1 study that may develop IED and present to the hospitals, a total of 240 patients with confirmed IED (30 patients per country) will be enrolled in the EXPECT-2 study in the same participating hospitals. The aim is to estimate the O-serotype distribution of ExPEC isolated from hospitalized patients aged between 60 and 85 years with invasive ExPEC disease, and to evaluate the clinical case definition and risk factors.

The results of these studies will provide critical information for designing and executing the Phase 3 clinical vaccine efficacy study.

The EXPECT studies will be managed by local study teams in each of the participating countries. These are led by COMBACTE partners such as Prof. Dr. Jesús Rodriguez-Bano (University Hospital of Seville, Spain), Prof. Dr. Oliver Cornely (University of Cologne, Germany), Prof. Dr. Evelina Tacconelli (University of Verona, Italy), and Dr. Olivier Barraud (CHU Limoges, France), and other collaborating parties.

Currently, the study protocols are being finalized and selection of participating sites will take place soon. Enrollment of study participants for both studies is expected to start in the 3rd quarter of 2019.


Important Pieces Of A Puzzle


Reflections On COMBACTE-NET


ASPIRE-ICU: Preventing Infection More Efficiently